BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 17638879)

  • 1. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
    Linardic CM; Naini S; Herndon JE; Kesserwan C; Qualman SJ; Counter CM
    Cancer Res; 2007 Jul; 67(14):6691-9. PubMed ID: 17638879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.
    Keller C; Arenkiel BR; Coffin CM; El-Bardeesy N; DePinho RA; Capecchi MR
    Genes Dev; 2004 Nov; 18(21):2614-26. PubMed ID: 15489287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.
    Naini S; Etheridge KT; Adam SJ; Qualman SJ; Bentley RC; Counter CM; Linardic CM
    Cancer Res; 2008 Dec; 68(23):9583-8. PubMed ID: 19047133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma.
    Hu Q; Yuan Y; Wang C
    PLoS One; 2013; 8(6):e68065. PubMed ID: 23799156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
    de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
    Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube.
    Finckenstein FG; Davicioni E; Osborn KG; Cavenee WK; Arden KC; Anderson MJ
    Transgenic Res; 2006 Oct; 15(5):595-614. PubMed ID: 16952014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma.
    Anderson J; Ramsay A; Gould S; Pritchard-Jones K
    Am J Pathol; 2001 Sep; 159(3):1089-96. PubMed ID: 11549601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.
    Armoni M; Quon MJ; Maor G; Avigad S; Shapiro DN; Harel C; Esposito D; Goshen Y; Yaniv I; Karnieli E
    J Clin Endocrinol Metab; 2002 Nov; 87(11):5312-24. PubMed ID: 12414908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells.
    Zhang Y; Wang C
    Oncogene; 2011 Aug; 30(32):3549-62. PubMed ID: 21423212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
    Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
    J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein.
    Xia SJ; Rajput P; Strzelecki DM; Barr FG
    Lab Invest; 2007 Apr; 87(4):318-25. PubMed ID: 17297479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator.
    Sublett JE; Jeon IS; Shapiro DN
    Oncogene; 1995 Aug; 11(3):545-52. PubMed ID: 7630639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR.
    Ebauer M; Wachtel M; Niggli FK; Schäfer BW
    Oncogene; 2007 Nov; 26(51):7267-81. PubMed ID: 17525748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27Kip1, a potential role for elevated Skp2 expression.
    Zhang L; Wang C
    J Biol Chem; 2003 Jan; 278(1):27-36. PubMed ID: 12401804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
    Barr FG
    Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal and rearranged PAX3 expression in human rhabdomyosarcoma.
    Frascella E; Toffolatti L; Rosolen A
    Cancer Genet Cytogenet; 1998 Apr; 102(2):104-9. PubMed ID: 9546061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene.
    Fredericks WJ; Ayyanathan K; Herlyn M; Friedman JR; Rauscher FJ
    Mol Cell Biol; 2000 Jul; 20(14):5019-31. PubMed ID: 10866659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts.
    Wang W; Slevin M; Kumar S; Kumar P
    Int J Oncol; 2005 Oct; 27(4):1087-96. PubMed ID: 16142327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas.
    Tarnowski M; Grymula K; Reca R; Jankowski K; Maksym R; Tarnowska J; Przybylski G; Barr FG; Kucia M; Ratajczak MZ
    Mol Cancer Res; 2010 Jan; 8(1):1-14. PubMed ID: 20068066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.